Open Access
Science advances, volume 7, issue 22
Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
Sham Nambulli
1, 2
,
Yufei Xiang
3
,
Natasha L. Tilston-Lunel
1, 2
,
Linda J. Rennick
1, 2
,
Zhe Sang
3, 4
,
William B. Klimstra
1, 2, 5
,
Douglas Reed
1, 5
,
Nicholas A. Crossland
6, 7
,
Yi Shi
3, 4
,
W. Paul Duprex
1, 2
1
Center for Vaccine Research, University of Pittsburgh, Pittsburgh, PA, USA.
|
2
Department of Microbiology and Molecular Genetics, University of Pittsburgh, Pittsburgh, PA, USA.
|
3
Department of Cell Biology, University of Pittsburgh, Pittsburgh, PA, USA.
|
5
Department of Immunology, University of Pittsburgh, Pittsburgh, PA, USA.
|
Publication type: Journal Article
Publication date: 2021-05-28
Multidisciplinary
Abstract
Aerosol delivery of an ultrapotent nanobody efficiently prevents and treats SARS-CoV-2 infection.
Found
Found
Top-30
Journals
|
1
2
3
4
5
6
|
|
|
Frontiers in Immunology
6 publications, 4.88%
|
|
|
Nature Communications
5 publications, 4.07%
|
|
|
Viruses
4 publications, 3.25%
|
|
|
International Journal of Biological Macromolecules
3 publications, 2.44%
|
|
|
Acta Pharmaceutica Sinica B
3 publications, 2.44%
|
|
|
Nanoscale
3 publications, 2.44%
|
|
|
Veterinary Pathology
2 publications, 1.63%
|
|
|
International Journal of Molecular Sciences
2 publications, 1.63%
|
|
|
Frontiers in Microbiology
2 publications, 1.63%
|
|
|
Pharmaceutical Research
2 publications, 1.63%
|
|
|
Cell Reports
2 publications, 1.63%
|
|
|
iScience
2 publications, 1.63%
|
|
|
Small Methods
2 publications, 1.63%
|
|
|
Proceedings of the National Academy of Sciences of the United States of America
2 publications, 1.63%
|
|
|
eLife
2 publications, 1.63%
|
|
|
PLoS Pathogens
2 publications, 1.63%
|
|
|
Antiviral Research
2 publications, 1.63%
|
|
|
Nature Chemical Biology
1 publication, 0.81%
|
|
|
Biochemical Society Transactions
1 publication, 0.81%
|
|
|
Nanomaterials
1 publication, 0.81%
|
|
|
Frontiers in Drug Discovery
1 publication, 0.81%
|
|
|
Frontiers in Nuclear Medicine
1 publication, 0.81%
|
|
|
Biomedicines
1 publication, 0.81%
|
|
|
Nature
1 publication, 0.81%
|
|
|
MRS Bulletin
1 publication, 0.81%
|
|
|
BioDrugs
1 publication, 0.81%
|
|
|
Scientific Reports
1 publication, 0.81%
|
|
|
Communications Biology
1 publication, 0.81%
|
|
|
Cell Discovery
1 publication, 0.81%
|
|
|
1
2
3
4
5
6
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Elsevier
32 publications, 26.02%
|
|
|
Springer Nature
20 publications, 16.26%
|
|
|
Cold Spring Harbor Laboratory
13 publications, 10.57%
|
|
|
Frontiers Media S.A.
11 publications, 8.94%
|
|
|
MDPI
9 publications, 7.32%
|
|
|
Wiley
5 publications, 4.07%
|
|
|
American Chemical Society (ACS)
4 publications, 3.25%
|
|
|
Taylor & Francis
4 publications, 3.25%
|
|
|
Public Library of Science (PLoS)
3 publications, 2.44%
|
|
|
Royal Society of Chemistry (RSC)
3 publications, 2.44%
|
|
|
SAGE
2 publications, 1.63%
|
|
|
Proceedings of the National Academy of Sciences (PNAS)
2 publications, 1.63%
|
|
|
eLife Sciences Publications
2 publications, 1.63%
|
|
|
American Society for Microbiology
2 publications, 1.63%
|
|
|
Portland Press
1 publication, 0.81%
|
|
|
Cambridge University Press
1 publication, 0.81%
|
|
|
American Society for Biochemistry and Molecular Biology
1 publication, 0.81%
|
|
|
European Molecular Biology Organization
1 publication, 0.81%
|
|
|
American Institute of Mathematical Sciences (AIMS)
1 publication, 0.81%
|
|
|
Federal Medical Biological Agency
1 publication, 0.81%
|
|
|
Hindawi Limited
1 publication, 0.81%
|
|
|
University of Nis
1 publication, 0.81%
|
|
|
The Royal Society
1 publication, 0.81%
|
|
|
Spandidos Publications
1 publication, 0.81%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.81%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Nambulli S. et al. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses // Science advances. 2021. Vol. 7. No. 22.
GOST all authors (up to 50)
Copy
Nambulli S., Xiang Y., Tilston-Lunel N. L., Rennick L. J., Sang Z., Klimstra W. B., Reed D., Crossland N. A., Shi Y., Duprex W. P. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses // Science advances. 2021. Vol. 7. No. 22.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1126/sciadv.abh0319
UR - https://doi.org/10.1126/sciadv.abh0319
TI - Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses
T2 - Science advances
AU - Nambulli, Sham
AU - Xiang, Yufei
AU - Tilston-Lunel, Natasha L.
AU - Rennick, Linda J.
AU - Sang, Zhe
AU - Klimstra, William B.
AU - Reed, Douglas
AU - Crossland, Nicholas A.
AU - Shi, Yi
AU - Duprex, W. Paul
PY - 2021
DA - 2021/05/28
PB - American Association for the Advancement of Science (AAAS)
IS - 22
VL - 7
SN - 2375-2548
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2021_Nambulli,
author = {Sham Nambulli and Yufei Xiang and Natasha L. Tilston-Lunel and Linda J. Rennick and Zhe Sang and William B. Klimstra and Douglas Reed and Nicholas A. Crossland and Yi Shi and W. Paul Duprex},
title = {Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses},
journal = {Science advances},
year = {2021},
volume = {7},
publisher = {American Association for the Advancement of Science (AAAS)},
month = {may},
url = {https://doi.org/10.1126/sciadv.abh0319},
number = {22},
doi = {10.1126/sciadv.abh0319}
}